Wellington Shields & Co. LLC Cuts Holdings in Pfizer Inc. (NYSE:PFE)

Wellington Shields & Co. LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 3.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 75,794 shares of the biopharmaceutical company’s stock after selling 2,608 shares during the quarter. Wellington Shields & Co. LLC’s holdings in Pfizer were worth $2,011,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in PFE. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the 4th quarter valued at $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer in the 4th quarter valued at $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in Pfizer in the 4th quarter valued at $28,000. Gladius Capital Management LP increased its holdings in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 38,015 shares in the last quarter. Finally, Noble Wealth Management PBC acquired a new stake in Pfizer in the 4th quarter valued at $31,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PFE. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. StockNews.com downgraded Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Citigroup lowered their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Up 0.5 %

NYSE:PFE opened at $25.74 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The stock has a 50-day simple moving average of $26.24 and a 200 day simple moving average of $27.15. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a market capitalization of $145.85 billion, a price-to-earnings ratio of 18.25, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter last year, the company posted $0.10 earnings per share. Pfizer’s revenue was up 24.7% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.